Why this matters: Three distinct ORTEX data signals have aligned on Boston Scientific within 48 hours — cost to borrow, short interest, and options sentiment. The convergence suggests a coordinated shift in trader positioning on the medical device maker.
Cost to borrow collapsed. Borrowing costs plunged 68% over the past week to just 0.14% APR, down from 0.50% on April 16. The sharp drop signals evaporating demand for short positions. When fewer traders want to borrow shares, lenders cut rates. The 0.14% level is the lowest since early April and down 59% from the month-ago reading of 0.34%.
Short interest retreated steadily. Short positions fell 11% over the past month to 23.3 million shares as of April 22. The decline accelerated in early April when shares shorted dropped from 25.7 million to 23.0 million in just eight trading days. Short interest now stands at 1.57% of free float. Days to cover sits at 1.43 based on recent average volume.
Options traders hedged aggressively. The put/call ratio spiked to 0.62 on April 21, jumping 54% above the 20-day average of 0.40. The move registered 2.9 standard deviations above normal levels. While short sellers exited, options traders piled into downside protection. The elevated PCR suggests some investors shifted from shorting shares to buying puts.
This is not the first time BSX has seen short interest decline while options sentiment turned defensive. Similar divergences occurred in late March when utilization dropped from 0.73 to 0.40 over two weeks. That episode also saw cost to borrow swing erratically — from 0.21% to 0.45% and back to 0.22% within eight trading days.
This is not financial advice. ORTEX data may contain inaccuracies.
See the live data behind this article on ORTEX.
Open BSX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
